New Drugs Could Make Tumour Cells More Sensitive to Radiotherapy
Posted by SR in News, tags: kinase, oncology
In the rare inherited human disease, ataxia-telangiectasia (A-T), a mutation is present in a gene encoding a protein that normally activates cellular responses to DNA damage. The mutation in the ATM gene leads to decreased ability to repair damaged DNA, and an increased sensitivity to ionising radiation and other DNA damaging agents. This highlights the ATM pathway as a potential target to increase the sensitivity of tumour cells to radiotherapy or chemotherapy. The ATM protein demonstrates kinase activity and a selective, small molecule inhibitor of this kinase, CP466722, has now been shown to enhance the sensitivity of tumour cells grown in vitro to ionising radiation.
Inhibition of ATM kinase activity is rapid, and is completely and rapidly reversed on wash-out; further experiments suggested that inhibition of ATM for a short period of time may be sufficient to sensitise tumour cell to radiotherapy. Because CP466722 is effective in murine cells as well as human cells, it may be possible to use mouse models to further explore the potential of using ATM inhibitors to increase the effectiveness of radiotherapy.
Related posts:
- New Approach could Starve Tumour Cells to Death Tumours are heterogeneous and contain both oxygenated and hypoxic regions. Cells in regions with low oxygen levels mainly use glucose...
- Targeting ‘Normal’ Cells to Treat Cancer Most cancer treatments directly target the cancerous cells but tumours are a heterogeneous mix of transformed cells and ‘normal’...
- Targeting ‘Normal’ Proteins to Kill Cancer Cells For the most part, cancer therapy has been aimed at exploiting pathways that are present in cancer cells and not...
- Mechanism of PPAR-γ Activators in Tumour Suppression Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that play essential roles in the regulation of cellular differentiation, development and metabolism....
- COX-2 Inhibitor Slows Basal Cell Carcinoma Researchers in the US have shown that the COX-2 inhibitor, celecoxib, can slow the development of basal cell carcinoma. Although...
Related posts brought to you by Yet Another Related Posts Plugin.
This entry was posted on Thursday, September 25th, 2008 at 8:33 am and is filed under News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.
Entries (RSS)